Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.…
Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication
Clearmind Medicine (NASDAQ: CMND) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 2.630 USD on 20 November 2026, down 99.7% over 52 weeks. Its 52-week range is 2.630 USD to 2076.80 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.33M USD.
Clearmind Medicine reports return on equity of -323.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 14.13M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.